"Serbia Pharmaceuticals & Healthcare Report Q4 2012" Now Available at Fast Market Research
BMI View: The Serbian drug market continues to be characterised by wholesale liquidity challenges and payment delays. In 2012, foreign pharmaceutical companies operating in the market have suffered as a result of the deterioration of the dinar, which has impacted repatriated revenues. The new government's increased focus on controlling drug price may be a concern, although the fact that the authorities are willing to tackle the causes of medicine supply shortages in the country gives some hope that provision of...
View full press release